Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, Matteucci P, Formelli F, Ravagnani F, Corradini P, Gianni AM. Carlo-Stella C, et al. Among authors: matteucci p. Blood. 2004 May 1;103(9):3287-95. doi: 10.1182/blood-2003-07-2428. Epub 2004 Jan 15. Blood. 2004. PMID: 14726397 Free article. Clinical Trial.
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, Astolfi M, Matteucci P, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C. Ladetto M, et al. Among authors: matteucci p. Biol Blood Marrow Transplant. 2006 Dec;12(12):1270-6. doi: 10.1016/j.bbmt.2006.07.007. Biol Blood Marrow Transplant. 2006. PMID: 17162208 Free article.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM. Di Nicola M, et al. Among authors: matteucci p. Blood. 2009 Jan 1;113(1):18-27. doi: 10.1182/blood-2008-06-165654. Epub 2008 Sep 22. Blood. 2009. PMID: 18809757 Free article. Clinical Trial.
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM. Viviani S, et al. Among authors: matteucci p. Leuk Lymphoma. 2010 Jul;51(7):1251-9. doi: 10.3109/10428194.2010.486090. Leuk Lymphoma. 2010. PMID: 20528244 Clinical Trial.
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM. Devizzi L, et al. Among authors: matteucci p. J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.
165 results